JAK Inhibitor: Mechanism, Uses & Side Effects
JAK inhibitors are medications that selectively block Janus kinases, used to treat inflammatory and autoimmune conditions.
Things worth knowing about "JAK inhibitor"
JAK inhibitors are medications that selectively block Janus kinases, used to treat inflammatory and autoimmune conditions.
What Is a JAK Inhibitor?
A JAK inhibitor (also known as a Janus kinase inhibitor or JAKi) is a type of medication that selectively blocks enzymes called Janus kinases (JAK). These enzymes play a key role in transmitting inflammatory signals inside cells. By inhibiting this signaling pathway, JAK inhibitors help control the overactive immune responses seen in autoimmune and inflammatory diseases.
Mechanism of Action
Janus kinases are intracellular enzymes linked to the JAK-STAT signaling pathway. When cytokines (such as interleukins or interferons) bind to cell surface receptors, they activate JAK enzymes, which in turn phosphorylate STAT proteins (Signal Transducers and Activators of Transcription). These proteins then travel to the cell nucleus and regulate the expression of genes involved in inflammation and immune responses.
JAK inhibitors disrupt this process by blocking JAK enzyme activity. There are four known Janus kinases: JAK1, JAK2, JAK3, and TYK2. Depending on the selectivity of a given JAK inhibitor, one or more of these enzymes may be targeted.
Indications (Approved Uses)
JAK inhibitors are used to treat a range of inflammatory and autoimmune conditions, including:
- Rheumatoid arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Atopic dermatitis (eczema)
- Ulcerative colitis and Crohn's disease
- Alopecia areata (patchy hair loss)
- Myelofibrosis and other hematologic disorders
Known JAK Inhibitors
Approved JAK inhibitors include:
- Tofacitinib (Xeljanz) – JAK1/JAK3 inhibitor
- Baricitinib (Olumiant) – JAK1/JAK2 inhibitor
- Upadacitinib (Rinvoq) – selective JAK1 inhibitor
- Ruxolitinib (Jakafi/Jakavi) – JAK1/JAK2 inhibitor, used in myelofibrosis
- Filgotinib (Jyseleca) – selective JAK1 inhibitor
Dosage and Administration
JAK inhibitors are typically taken as oral tablets or capsules, which is a key advantage over biologic therapies that usually require injection or infusion. Some JAK inhibitors are also available as topical formulations (e.g., creams for skin conditions). The appropriate dosage depends on the indication, the specific drug, and the individual patient profile, and must always be prescribed by a physician.
Side Effects
As with all immunomodulating medications, JAK inhibitors can cause side effects, including:
- Increased risk of infections (e.g., herpes zoster, upper respiratory infections)
- Blood count changes (decreased red or white blood cell counts)
- Elevated blood lipid levels (hyperlipidemia)
- Liver enzyme abnormalities
- In rare cases: increased risk of thromboembolic events (blood clots) and cardiovascular events
- Possible increased risk of malignancy in certain patient groups
Regular monitoring and follow-up appointments are required during treatment with JAK inhibitors.
Contraindications and Precautions
JAK inhibitors should be used with caution or avoided in the following situations:
- Active infections (particularly tuberculosis)
- Severe renal or hepatic impairment
- Pregnancy and breastfeeding
- Elevated cardiovascular risk or history of thrombosis
- Patients over 65 years of age (increased risk profile)
JAK Inhibitors Versus Biologics
Compared to biologic therapies (e.g., TNF blockers), JAK inhibitors offer the advantage of oral administration and potentially faster onset of action. Biologics are highly specific monoclonal antibodies that target individual cytokines or receptors, while JAK inhibitors act on a broader intracellular signaling pathway. The choice between these treatment options depends on the specific disease, the patient's risk profile, and their response to prior therapies.
References
- Schwartz DM, Kanno Y, Villarino A, et al. - JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery, 2017.
- European Medicines Agency (EMA) - Product information for approved JAK inhibitors (baricitinib, tofacitinib, upadacitinib, ruxolitinib). https://www.ema.europa.eu
- Smolen JS, Landewé RBM, et al. - EULAR recommendations for the management of rheumatoid arthritis. Annals of the Rheumatic Diseases, 2023.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Most purchased products
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®Most read entries
3 Posts in this encyclopedia categoryMagnesiumcarbonat
Calorie content
Cologne list
Related search terms: JAK inhibitor